Search the Newsreel

Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00

Wells Fargo & Company has lowered its price target for Cabaletta Bio (NASDAQ:CABA) from $4.00 to $3.00, while maintaining an "equal weight" rating, suggesting a potential upside of 12.57%. Analyst opinions are varied, with MarketBeat reporting a "Moderate Buy" consensus and a $15.33 average …

Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake

T. Rowe Price Investment Management, Inc. has reported an 11.6% ownership stake in Cabaletta Bio (CABA) common stock, amounting to 18,869,907 shares. The firm holds sole voting power over 18,776,448 shares and sole dispositive power over all 18,869,907 shares, explicitly denying beneficial ownership despite …

Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position

Bain Capital Life Sciences Opportunities III, L.P. has reported a 9.99% beneficial ownership stake in Cabaletta Bio (CABA), as detailed in a recent SCHEDULE 13G/A filing. This ownership comprises 7,709,188 common shares, a warrant for up to 7,500,000 shares, and a pre-funded warrant for …

Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS

Cabaletta Bio (NASDAQ:CABA) reported a quarterly loss of $0.34 per share, exceeding analyst estimates by $0.03. Despite beating estimates, the stock fell to $2.73 during midday trading, significantly below its 52-week high of $4.23. Analysts maintain a "Moderate Buy" rating with an average price …

Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress

TD Cowen has reiterated its Buy rating on Cabaletta Bio (NASDAQ:CABA) due to the company's progress in its RESET clinical trial portfolio. The stock has shown strong performance with a 30% year-to-date gain and 67% over the past year. Cabaletta Bio's pivotal trial data …

Cabaletta Bio (CABA) Q2 Earnings Beat Expectations; Market Focuses on Growth Potential Despite Losses

Cabaletta Bio reports Q2 2026 net loss of $51.0M; cash position $225.1M supports operations into mid-2027

Cabaletta Bio reported a net loss of $51.0 million for Q2 2026, with operating expenses of $52.0 million. The company's cash position of $225.1 million, as of June 30, 2026, is expected to fund operations into mid-2027. Cabaletta also highlighted progress in its RESET …

Cabaletta Bio Reports $51.0 Million Second-Quarter Net Loss

Cabaletta Bio reported a net loss of $51.0 million, or $0.34 per share, for the second quarter of 2026, with research and development expenses at $44.4 million. The company ended the quarter with $225.1 million in cash, expected to fund operations into mid-2027, and …

Cabaletta Bio, Inc. 2Q 2026: Net loss $(51.0)M, EPS $(0.34) — 10-Q Summary

Cabaletta Bio, Inc. reported a net loss of $(51.0)M for the second quarter of 2026, with a diluted loss per share of $(0.34). The company remains pre-revenue, focusing on advancing multiple RESET™ clinical programs and scaling manufacturing. They have achieved clinical progress with positive …

Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA

Cabaletta Bio (CABA) announced its second quarter 2026 financial results, reporting a net loss of $51.0 million but increasing its cash, cash equivalents, and short-term investments to $225.1 million, which is expected to fund operations into mid-2027. The company is advancing its lead CAR …

Form 8K Cabaletta Bio Inc For: 13 August By Investing.com

This article reports on Cabaletta Bio Inc.'s Form 8K filing for August 13th, as published by Investing.com. It is a brief announcement without further details within the provided text. The article is primarily a stub, directing readers to a comments section.

CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial

Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares

Adage Capital Management, L.P. and its related parties have disclosed an 8.43% beneficial ownership stake in Cabaletta Bio, Inc. (CABA). This stake totals 14,174,758 shares of Common Stock, which includes 5,000,000 shares exercisable from warrants held by Adage Capital Partners, L.P. The filing indicates …

Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares

Norges Bank, the central bank of Norway, has reported a 5.382% beneficial ownership stake in Cabaletta Bio, Inc. (CABA), amounting to 8,775,653 common shares as of June 30, 2026. The filing indicates Norges Bank holds significant sole voting power over these shares, with some …

Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview

Cabaletta Bio, Inc. is anticipated to report a loss of 37 cents per share. This information is part of an earnings preview, indicating upcoming financial results for the company. The article provides a headline and an opportunity to read the full report on TradingView.

Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cabaletta Bio Inc (CABA) currently trades at $2.79, with analysts forecasting a significant upside potential of 433.13% to a target price of $14.50. Based on ratings from 10 analysts, the stock has a "Buy" consensus, with the highest forecast at $22.00 and the lowest …

Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside

Cabaletta Bio, Inc. (CABA) has seen its average 12-month price target raised to $14.71 by analysts, implying a significant 427% potential upside from its recent closing price. This new target is based on estimates from 7 analysts, with individual forecasts ranging from $4 to …

Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio

Vanguard Capital Management has reported a passive stake of 8.30 million shares, representing 5.08% of Cabaletta Bio Inc.'s common stock, through a Schedule 13G filing. This filing indicates that Vanguard and its affiliates beneficially own these shares, with sole voting power over 1.07 million …

Millennium Management Reduces Stake in Cabaletta Bio (CABA) by Nearly 65%

Millennium Management LLC has significantly reduced its stake in Cabaletta Bio (CABA) by nearly 65%, selling over 3.8 million shares. This move signals decreased confidence in Cabaletta Bio's near-term prospects due to its negative profitability, poor growth, and low GF Score, despite strong price …

Cabaletta Bio (CABA) to Post Earnings on Thursday

Cabaletta Bio (CABA) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts anticipate a loss of $0.37 per share and revenues around $1.67 million, with a conference call set for August 7th. The company had previously beaten …

CABA|Cabaletta Bio Inc|Price:2.720|Chg%:+0.030

Cabaletta Bio Inc. (CABA) closed at $2.715 with a slight decrease of 0.18%. The company has a market capitalization of $302.25 million, and analysts currently rate it as a "Buy" with a target price indicating a potential 447.00% upside. Cabaletta Bio is a clinical-stage …

Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Cabaletta Bio Inc (CABA), detailing its performance by business segment and region. However, it explicitly states that the relevant financial data for these breakdowns has not yet been disclosed by the company. The page displays current stock …

Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cabaletta Bio Inc (CABA) stock information, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years. The page also presents current stock pricing, market capitalization, …

Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a collective beneficial ownership of 2,068,491 shares of Cabaletta Bio (CABA) common stock, representing a 1.3% stake. This information was disclosed in an amended passive investment filing (SCHEDULE 13G/A). The reporting …

Cabaletta Bio (CABA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Cabaletta Bio (CABA) presented at the Guggenheim Securities Inaugural Healthcare Innovation Conference, highlighting its progress in developing targeted CAR T cell therapies for autoimmune diseases. The company is advancing CABA-201, a fully human CAR T product, with ambitious goals for registrational trials in 2025, …

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Moderate Buy" by Analysts

Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average analyst rating of "Moderate Buy" from seven firms, with an average 1-year price target of $15.50. Recent analyst actions were mixed, including Guggenheim raising its target to $16 and Morgan Stanley cutting its target to $13. …

Cabaletta Bio (CABA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Cabaletta Bio (CABA) provided a summary of its Guggenheim Securities Emerging Outlook: Biotech Summit 2026 presentation, highlighting strategic program updates including pivotal myositis study enrollment, automated manufacturing for rese-cel, and upcoming Phase 1/2 data for autoimmune diseases. The company detailed its clinical trial design, …

ETFs Investing in Cabaletta Bio, Inc. Stocks

This article lists various ETFs that include Cabaletta Bio, Inc. (CABA) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of CABA stock, issuer, management style, expense ratio, AUM, price, and performance metrics. The ETFs cover …